Talk:Risankizumab
Appearance
This is the talk page for discussing improvements to the Risankizumab article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Risankizumab.
|
-rzaa?
[edit]I came here hoping to learn the etymology of the very unusual suffix -rzaa in risankizumab-rzaa. Could someone please add an explanation?
According to https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761105Orig1s000NameR.pdf, it is "devoid of meaning." Why add those extra five characters, -rzaa, if they are devoid of meaning? (talk) 15:21, 23 July 2024 (UTC)